Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of bapineuzumab in Alzheimer's disease
2011-002133-20Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Johnson & Johnson. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Aug 2011; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-002133-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002133-20.